Evidence map›Paper›PMID 37647437›Full record

ArticleImmunity, inflammation and disease2023

Severe hemolytic exacerbations of Chinese PNH patients infected SARS-CoV-2 Omicron.

Hui Yang, Xingxing Chai, Yuemin Gong, Xinyu Zhang, Lingling Wang, Xin Zhou, Xiaoyu Chen, Jinge Xu, Dan Xu, Guangsheng He and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunity, inflammation and disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Hui YangKey Laboratory of Hematology of Nanjing Medical University, Department of Hematology, Collaborative Innovation Center for Cancer Personalize, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu, China.
Xingxing ChaiDepartment of Hematology, The Second People's Hospital of Lianyungang, Lianyungang, Jiangsu, China.
Yuemin GongKey Laboratory of Hematology of Nanjing Medical University, Department of Hematology, Collaborative Innovation Center for Cancer Personalize, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu, China.
Xinyu ZhangKey Laboratory of Hematology of Nanjing Medical University, Department of Hematology, Collaborative Innovation Center for Cancer Personalize, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu, China.
Lingling WangDepartment of Hematology, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, Jiangsu, China.
Xin ZhouDepartment of Hematology, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, Jiangsu, China.
Xiaoyu ChenKey Laboratory of Hematology of Nanjing Medical University, Department of Hematology, Collaborative Innovation Center for Cancer Personalize, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu, China.
Jinge XuDepartment of Hematology, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Dan XuDepartment of Hematology, Funing People's Hospital, Yancheng, Jiangsu, China.
Guangsheng HeKey Laboratory of Hematology of Nanjing Medical University, Department of Hematology, Collaborative Innovation Center for Cancer Personalize, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu, China.ORCID 0000-0002-3944-5897
Jianyong LiKey Laboratory of Hematology of Nanjing Medical University, Department of Hematology, Collaborative Innovation Center for Cancer Personalize, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu, China.
Jiangsu Cancer Hospital · CNWuxi People's Hospital · CNNantong University · CNThe First People’s Hospital of Lianyungang · CNXuzhou Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionParoxysmal nocturnal hemoglobinuria (PNH) is characterized by hemolytic anemia, bone marrow failure, thrombophilia. COVID-19, caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with many variants including Omicron.

methodsThis study collected demographic and clinical data of 20 PNH patients with SARS-CoV-2 Omicron infection.

resultsThey all were with high disease activity, and LDH level exceeded any documented since the diagnosis of PNH, and those reported in the literature for previously stable treatment with complement inhibitors. D-dimer level elevated in 10 patients. 2 patients developed mild pulmonary artery hypertension. Glomerular filtration rate declined in 5 patients. 1 patient developed acute renal failure and underwent hemodialysis. Anemia and hemolysis were improved in 5 patients treated with eculizumab.

conclusionsHemolytic exacerbation of PNH with COVID-19 is severe and eculizumab may be an effective treatment.

Indexed as

COVID-19Hemoglobinuria, ParoxysmalHemolysisEast Asian PeopleHumansSARS-CoV-2complement inhibitor therapyCOVID-19hemolysisOmicronparoxysmal nocturnal hemoglobinuria

Identifiers

PMID37647437
PMCPMC10408369
OpenAlexW4385666034

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.